Cassava Sciences, Inc. Warrant (SAVAW) Research

Cassava Sciences, Inc. is a biotechnology firm currently in the clinical development stage, dedicated to discovering therapies for neurodegenerative disorders. Their key therapeutic asset is simufilam, a small molecule drug that has already completed its Phase 2b clinical evaluation. Furthermore, the company is advancing SavaDx, a diagnostic tool utilizing blood-based biomarkers for the early detection of Alzheimer's disease. Incorporated in 1998, the organization was previously known as Pain Therapeutics, Inc. until its name change to Cassava Sciences, Inc. in March 2019. The company's headquarters are located in Austin, Texas.

Market snapshot

Symbol
SAVAW
Price
$0.03
Day change
0.00%
Market cap
$1.4M
52-week range
0.02-11.02
Sector
Healthcare
Industry
Biotechnology

Peer companies

  • ASLAN Pharmaceuticals Limited (ASLN)
  • CohBar, Inc. (CWBR)
  • Altamira Therapeutics Ltd. (CYTO)
  • NAYA Biosciences, Inc. (NAYA)
  • NeuBase Therapeutics, Inc. (NBSE)
  • 9 Meters Biopharma, Inc. (NMTRQ)
  • OncoSec Medical Incorporated (ONCSQ)
  • Oncternal Therapeutics, Inc. (ONCT)

Open Cassava Sciences, Inc. Warrant (SAVAW) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.